SNDX
Syndax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.56
−0.58%Aug 4, 2026, 20:01 UTC
Syndax Pharmaceuticals reported second quarter 2026 financial results, with total revenue of $73 million, a 92% year-over-year increase.
Jul 14, 2026, 20:03 UTC
Syndax Pharmaceuticals introduced two pipeline assets aimed at non-small cell lung cancer and myelofibrosis at a company R&D event.
Source:Jun 10, 2026, 00:00 UTC
Syndax Pharmaceuticals issued $250.0 million of 2.25% Convertible Senior Notes due 2031, with net proceeds of approximately $243.0 million for general corporate purposes.
Jun 4, 2026, 00:00 UTC
Syndax Pharmaceuticals Inc completed a private placement of $250 million 2.25% convertible senior notes due 2031 on June 10, 2026.
Source: